1.Changes in Candidemia during the COVID-19 Pandemic: Species Distribution, Antifungal Susceptibility, Initial Antifungal Usage, and Mortality Trends in Two Korean Tertiary Care Hospitals
Ahrang LEE ; Minji KIM ; Sarah KIM ; Hae Seong JEONG ; Sung Un SHIN ; David CHO ; Doyoung HAN ; Uh Jin KIM ; Jung Ho YANG ; Seong Eun KIM ; Kyung-Hwa PARK ; Sook-In JUNG ; Seung Ji KANG
Chonnam Medical Journal 2025;61(1):52-58
This study aimed to investigate changes in candidemia incidence, species distribution, antifungal susceptibility, initial antifungal use, and mortality trends in Korea before and during the COVID-19 pandemic. A retrospective analysis was conducted on candidemia cases from two tertiary care hospitals in Korea between 2017 and 2022. Data were compared between the pre-pandemic (2017-2019) and pandemic (2020-2022) periods. Statistical methods included incidence rate ratios (IRRs) and multivariate Cox regression to assess 30-day mortality risk factors. A total of 470 candidemia cases were identified, with 48.7% occurring pre-pandemic and 51.3% during the pandemic. While the overall incidence of candidemia remained similar across the two periods (IRR 1.15;p=0.13), the incidence in intensive care units (ICUs) significantly increased during the pandemic (IRR 1.50; p<0.01). The distribution of Candida species did not differ significantly between the two periods. Fluconazole non-susceptibility in C. albicans markedly decreased (10.0% vs. 0.9%, p<0.01), whereas C. glabrata exhibited a significant rise in caspofungin non-susceptibility during the pandemic (0% vs. 22.4%, p<0.01).Echinocandin use increased (21.8% vs. 34.4%; p<0.01), while fluconazole use declined (48.0% vs. 32.8%; p<0.01). Although the 30-day mortality rate was higher during the pandemic (60.2% vs. 57.2%), the difference was not statistically significant (p=0.57).The findings highlight the need for region-specific surveillance and tailored management strategies to improve candidemia outcomes, especially during healthcare disruptions like the COVID-19 pandemic.
2.Changes in Candidemia during the COVID-19 Pandemic: Species Distribution, Antifungal Susceptibility, Initial Antifungal Usage, and Mortality Trends in Two Korean Tertiary Care Hospitals
Ahrang LEE ; Minji KIM ; Sarah KIM ; Hae Seong JEONG ; Sung Un SHIN ; David CHO ; Doyoung HAN ; Uh Jin KIM ; Jung Ho YANG ; Seong Eun KIM ; Kyung-Hwa PARK ; Sook-In JUNG ; Seung Ji KANG
Chonnam Medical Journal 2025;61(1):52-58
This study aimed to investigate changes in candidemia incidence, species distribution, antifungal susceptibility, initial antifungal use, and mortality trends in Korea before and during the COVID-19 pandemic. A retrospective analysis was conducted on candidemia cases from two tertiary care hospitals in Korea between 2017 and 2022. Data were compared between the pre-pandemic (2017-2019) and pandemic (2020-2022) periods. Statistical methods included incidence rate ratios (IRRs) and multivariate Cox regression to assess 30-day mortality risk factors. A total of 470 candidemia cases were identified, with 48.7% occurring pre-pandemic and 51.3% during the pandemic. While the overall incidence of candidemia remained similar across the two periods (IRR 1.15;p=0.13), the incidence in intensive care units (ICUs) significantly increased during the pandemic (IRR 1.50; p<0.01). The distribution of Candida species did not differ significantly between the two periods. Fluconazole non-susceptibility in C. albicans markedly decreased (10.0% vs. 0.9%, p<0.01), whereas C. glabrata exhibited a significant rise in caspofungin non-susceptibility during the pandemic (0% vs. 22.4%, p<0.01).Echinocandin use increased (21.8% vs. 34.4%; p<0.01), while fluconazole use declined (48.0% vs. 32.8%; p<0.01). Although the 30-day mortality rate was higher during the pandemic (60.2% vs. 57.2%), the difference was not statistically significant (p=0.57).The findings highlight the need for region-specific surveillance and tailored management strategies to improve candidemia outcomes, especially during healthcare disruptions like the COVID-19 pandemic.
3.Changes in Candidemia during the COVID-19 Pandemic: Species Distribution, Antifungal Susceptibility, Initial Antifungal Usage, and Mortality Trends in Two Korean Tertiary Care Hospitals
Ahrang LEE ; Minji KIM ; Sarah KIM ; Hae Seong JEONG ; Sung Un SHIN ; David CHO ; Doyoung HAN ; Uh Jin KIM ; Jung Ho YANG ; Seong Eun KIM ; Kyung-Hwa PARK ; Sook-In JUNG ; Seung Ji KANG
Chonnam Medical Journal 2025;61(1):52-58
This study aimed to investigate changes in candidemia incidence, species distribution, antifungal susceptibility, initial antifungal use, and mortality trends in Korea before and during the COVID-19 pandemic. A retrospective analysis was conducted on candidemia cases from two tertiary care hospitals in Korea between 2017 and 2022. Data were compared between the pre-pandemic (2017-2019) and pandemic (2020-2022) periods. Statistical methods included incidence rate ratios (IRRs) and multivariate Cox regression to assess 30-day mortality risk factors. A total of 470 candidemia cases were identified, with 48.7% occurring pre-pandemic and 51.3% during the pandemic. While the overall incidence of candidemia remained similar across the two periods (IRR 1.15;p=0.13), the incidence in intensive care units (ICUs) significantly increased during the pandemic (IRR 1.50; p<0.01). The distribution of Candida species did not differ significantly between the two periods. Fluconazole non-susceptibility in C. albicans markedly decreased (10.0% vs. 0.9%, p<0.01), whereas C. glabrata exhibited a significant rise in caspofungin non-susceptibility during the pandemic (0% vs. 22.4%, p<0.01).Echinocandin use increased (21.8% vs. 34.4%; p<0.01), while fluconazole use declined (48.0% vs. 32.8%; p<0.01). Although the 30-day mortality rate was higher during the pandemic (60.2% vs. 57.2%), the difference was not statistically significant (p=0.57).The findings highlight the need for region-specific surveillance and tailored management strategies to improve candidemia outcomes, especially during healthcare disruptions like the COVID-19 pandemic.
4.Vitrectomy as a Treatment for Vitreous Floaters: A Review
Jiwon BAEK ; Seung Min LEE ; Yong-Sok JI ; Un Chul PARK ; Kyu Hyung PARK ;
Journal of Retina 2025;10(2):127-134
Vitreous floaters are a common ophthalmic symptom caused by age-related vitreous degeneration, trauma, or other ocular conditions.Patients typically describe floaters as moving shadows or thread-like opacities in their visual field, which can cause significant visual and psychological discomfort. While most cases improve over time through natural neuroadaptation, some patients experience persistent symptoms that impact quality of life and seek active treatment. Despite various therapeutic attempts—including Nd:YAG vitreolysis, pharmacologic vitreolysis, and pars plana vitrectomy (PPV)—no standardized treatment guideline has been established. Among those proposed, PPV is the most direct method to remove floaters, but it poses considerable risks, including cataract formation, retinal tears, retinal detachment, and endophthalmitis. Additionally, its subjective efficacy raises concerns about inconsistent outcomes. This review explores the pathophysiology of vitreous changes leading to floaters and critically evaluates the efficacy and safety of PPV for floater treatment based on current literature and the results of a survey conducted by the Korean Retina Society. The survey indicates that most specialists prefer observation and patient counseling over surgery, citing high complication risks, limited benefits, and ethical concerns.Floater management should prioritize conservative approaches, and PPV should be considered only in highly selected cases following thorough evaluation and counseling. Continued research into safer and more effective treatments is essential for addressing this common yet complex clinical issue.
5.Association between Moyamoya Disease and Secondary Glaucoma: A Nationwide Retrospective Cohort Study
Min Seok KIM ; Seonghee NAM ; Eun Ji LEE ; Si Un LEE ; Jeongwoo LEE ; Kwangsic JOO
Journal of Retina 2025;10(2):144-149
Purpose:
This nationwide longitudinal cohort study aims to investigate the association between Moyamoya disease (MMD) and subsequent development of secondary glaucoma.
Methods:
The records of patients with MMD and a control group between 2002 and 2022 were extracted from the Korean National Health Insurance Service database. Cases with MMD diagnosed in the first two years of the study period and cases with any glaucoma diagnosed prior to MMD were excluded. Cox proportional hazard models were used to assess the association of MMD with secondary glaucoma. Kaplan–Meier survival analysis with a log-rank test was performed to compare the incidence probability of secondary glaucoma between MMD patients and controls.
Results:
A total of 36,432 patients with a diagnostic code for MMD and age-/sex-matched non-MMD controls (n = 346,769) were included. Cox regression analysis showed that MMD was associated with increased risk of secondary glaucoma (adjusted hazard ratio, 2.42; 95% confidence interval, 1.84–3.18; p < 0.001). Other risk factors included male sex, older age, hypertension, diabetes, and peripheral artery disease. The incidence probability of secondary glaucoma was significantly higher in MMD patients compared to controls (p < 0.001).
Conclusions
Patients with MMD face elevated risk of developing secondary glaucoma, indicating that MMD may be a potential risk factor for secondary glaucoma.
6.First Reported Case of Prosthetic Joint Infection Caused by Lomentospora prolificans in an Immunocompetent Host
Yoonjung LEE ; Soosung KIM ; Hong Yeol YANG ; Ahrang LEE ; Minji KIM ; Hae Seong JEONG ; Sung Un SHIN ; Uh Jin KIM ; Kyung-Hwa PARK ; Sook-In JUNG ; Seung Ji KANG
Korean Journal of healthcare-associated Infection Control and Prevention 2025;30(1):76-80
Lomentospora prolificans is a rare opportunistic mold with high intrinsic resistance to most antifungal agents. It causes disseminated infections in immunocompromised patients and localized infections in immunocompetent hosts, often involving the bones, joints, or skin. However, prosthetic joint infections (PJI) due to L. prolificans have not been previously reported.Here, we describe the first case of L. prolificans PJI in an immunocompetent 51-year-old male patients, who had no significant comorbidities other than hypertension. The patient presented with right knee pain and swelling one year after total knee arthroplasty. Cultures of the joint fluid and periprosthetic tissue yielded L. prolificans, as confirmed by matrix-assisted laser desorption ionization–time-of-flight mass spectrometry (MALDI-TOF MS) and rRNA gene sequencing. Susceptibility testing showed high minimum inhibitory concentrations for most currently available antifungal agents, including azoles, amphotericin B, echinocandins, and terbinafine. Despite prosthesis removal, multiple surgical debridements, and prolonged antifungal therapy, including voriconazole and terbinafine, the infection persisted over a five-year period.Amputation was discussed as a potential curative measure; however, no consensus has been reached due to its long-term impact. This case highlights the clinical challenges of managing L. prolificans PJI and underscores the need for novel antifungal therapies to treat rare drugresistant fungal infections.
7.Isolated Axillary Skin Recurrence as the First Sign of Breast CancerRelapse 20 Years After Initial Treatment: A Case Report
Hye Un MA ; Yong Min NA ; Hee Won RYU ; Sang Ho JO ; Young Jae RYU ; Sang Chun PARK ; Yong Bin KWON ; Jin Seong CHO ; Ji Shin LEE ; Min Ho PARK
Journal of Breast Disease 2025;13(1):9-12
Hormone receptor-positive (HR+) breast cancer is known for its potential to recur many years after initial treatment. Although most recurrences occur within the first 5–10 years, late recurrence, especially beyond 15 years of age, is rare and isolated cutaneous recurrence is even less frequently reported. However, awareness of the possibility of extremely late and subtle local recurrences in patients with HR+ breast cancer has gradually increased over time. Clinicians should remain vigilant for atypical cutaneous changes near previous surgical sites, even decades after the initial treatment, and consider biopsy in the absence of classic signs of recurrence. We report the case of a 56-year-old woman who experienced an isolated cutaneous recurrence nearly 20 years after mastectomy for HR+ breast cancer, presenting with only faint erythema.
8.Influence of varying cement types and abutment heights on pull-off force of zirconia restorations
Yeong-Jun JUNG ; Yu-Lee KIM ; Ji-Hye JUNG ; Nae-Un KANG ; Hyun-Jun KONG
Journal of Dental Rehabilitation and Applied Science 2024;40(2):64-71
Purpose:
The purpose of this study is to evaluate Ti-base abutment’s three different heights and three different cement types on the pull-off force of zirconia-based restorations.
Materials and Methods:
A total of 90 fixture lab analogs were embedded in auto polymerizing resin bloack. 90 Ti-base abutments heights of 3 mm, 5 mm, 7 mm were scanned and zirconia restoration were prepared from scanned files. Zirconia restoration were cemented with three different types of cements (temporary, semi-permanent, permanent) following manufacturer’s instructions. All 90 specimens were placed and tested in a universal testingmachine for pull-out testing. Retention was measured by recording the force at load drop. Statistical analysis was performedusing Kruskal-Wallis test for detecting whether there are any statistical significance along cement types or abutment heights.After that, Mann-Whitney test was used for figuring out differences regarding abutment height and the comparison between 3cements.
Results:
Temp bond showed significantly lower pull-off force compared to Fujicem regardless of any abutment height.However, there were significant differences between Cem-implant and Fujicem in abutment height of 3 mm and 7 mm, but there was no significant difference in 5 mm. Temp bond and Cem-implant had significant differences only in abutment height of 5 mm.
Conclusion
Although Ti-base abutment height did not influenced zirconia restorations’ retentiveness, cement types showed significant differences.
9.Dental Age Estimation in Children Using Convolution Neural Network Algorithm: A Pilot Study
Byung-Yoon ROH ; Hyun-Jeong PARK ; Kyung-Ryoul KIM ; In-Soo SEO ; Yeon-Ho OH ; Ju-Heon LEE ; Chang-Un CHOI ; Yo-Seob SEO ; Ji-Won RYU ; Jong-Mo AHN
Journal of Oral Medicine and Pain 2024;49(4):118-123
Purpose:
Recently, deep learning techniques have been introduced for age estimation, with automated methods based on radiographic analysis demonstrating high accuracy. In this study, we applied convolutional neural network (CNN) techniques to the lower dentition area on orthopantomograms (OPGs) of children to develop an automated age estimation model and evaluate its accuracy for use in forensic dentistry.
Methods:
In this study, OPGs of 2,856 subjects aged 3-14 years were analyzed. The You Only Look Once (YOLO) V8 object detection technique was applied to extract the mandibular dentition area on OPGs, designating it as the region of interest (ROI). First, 200 radiographs were randomly selected, and were used to train a model for extracting the ROI. The trained model was then applied to the entire dataset. For the CNN image classification task, 80% of OPGs were allocated to the training set, while the remaining 20% were used as the test set. A transfer learning approach was employed using the ResNet50 and VGG19 backbone models, with an ensemble technique combining these models to improve performance. The mean absolute error (MAE) on the test set was used as the validation metric, and the model with the lowest MAE was selected.
Results:
In this study, the age estimation model developed using mandibular dentition region from OPGs achieved MAE and root mean squared error (RMSE) values of 0.501 and 0.742, respectively, on the test set, and MAE and RMSE values of 0.273 and 0.354, respectively, on the training set.
Conclusions
The automated age estimation model developed in this study demonstrated accuracy comparable to that of previous research and shows potential for applications in forensic investigations. Increasing the sample size and incorporating diverse deep learning techniques are expected to further enhance the accuracy of future age estimation models.
10.Aging with HIV: The Burden of Comorbidities, Polypharmacy, and Drug Interactions in Korean People Living withHIV Aged ≥50 Years
Jin KIM ; Hyun-Ju NAM ; Ji-Yeon KIM ; Mi-Kyung HEO ; Sung Un SHIN ; Uh Jin KIM ; Seong Eun KIM ; Seung-Ji KANG ; Jihwan BANG ; Jin-Soo LEE ; Mi-Ok JANG ; Kyung-Hwa PARK
Infection and Chemotherapy 2024;56(4):534-543
Background:
The life expectancy of people living with human immunodeficiency virus (PLWH) has significantly improved with advancements in antiretroviral therapy (ART). However, aging PLWH face a growing burden of noncommunicable diseases (NCDs), polypharmacy, and drug-drug interactions (DDIs), which pose challenges in their management. This study investigates the prevalence of NCDs, polypharmacy, and DDIs among PLWH aged ≥50 years in Korea and their impact on quality of life (QOL).
Materials and Methods:
A cross-sectional study was conducted among 243 PLWH aged ≥50 years receiving ART for at least three months at three university hospitals in Korea between January and July 2022. Data were collected through electronic medical records and personal interviews, assessing demographics, comorbidities, polypharmacy, ART adherence, and QOL using the Korean version of WHOQOL-HIV BREF scale. Potential DDIs were analyzed using the University of Liverpool HIV Drug Interaction Database, and potentially inappropriate medications (PIMs) were identified using the 2023 American Geriatrics Society Beers Criteria. We classified participants into three age groups:50–<65 years, 65–<75 years, and ≥75 years.
Results:
The prevalence of comorbidities was 71.6%, with older participants (≥75 years) showing a significantly higher burden, including bone diseases, osteoarthritis, and dementia (P<0.001). Polypharmacy was observed in 28.4% of participants and increased with age, with 53.3% of those aged ≥75 years taking ≥10 pills daily.Polypharmacy was associated with poorer QOL (71.6 vs. 76.6, P=0.010). Amber-flag DDIs were found in 81 participants (33.3%), most commonly involving metformin and divalent cations. No red-flag DDIs were identified.PIMs were observed in 6.6% of participants aged ≥65 years.
Conclusion
Aging PLWH in Korea face significant challenges from comorbidities, polypharmacy, and DDIs, which negatively impact QOL. Integrated, age-specific, and multidisciplinary care strategies are urgently needed to improve outcomes and ensure the well-being of older PLWH.

Result Analysis
Print
Save
E-mail